Septerna
Latest round
- Series B
Last raised
- Jun 2023
Total raised
- $174M
Investors
- 15
About Septerna
Based in California, US, and founded in 2019 by CEO Jeffrey Finer, Robert Lefkowitz, Arthur Christopoulos, and Patrick Sexton, Septerna, Inc. operates as a biotech company that develops an industrialized platform by combining the latest advances in biochemical, structural and computational drug discovery approaches to precisely control and modulate GPCR (G protein-coupled receptors) biology and pharmacology to discover and develop medicines. In July 2023, Septerna, Inc. The company utilizes its proprietary native complex platform to recapitulate G protein-coupled receptors (GPCRs) with their dynamics, functions, and structures apart from the cellular environment to facilitate industrial-scale drug discovery for a wide range of diseases. Septerna’s pipeline includes GPCR medicines that target endocrine, CNS, and inflammation. In October 2024, Septerna, Inc." Septerna, Inc.4 million shares of common stock as part of the listing., respectively.
Who invested in Septerna
15 investors across 2 rounds
See all investors in Septerna
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Septerna
Who invested in Septerna?
Septerna has 15 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Septerna raised?
Septerna has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Septerna last raise money?
Septerna's most recent round on record is a Series B, in Jun 2023.
What does Septerna do?
Based in California, US, and founded in 2019 by CEO Jeffrey Finer, Robert Lefkowitz, Arthur Christopoulos, and Patrick Sexton, Septerna, Inc.
Where is Septerna headquartered?
Septerna is headquartered in San Francisco, US.
Which VCs invest in companies like Septerna?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Septerna's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Septerna? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.